Affordable and Safe Prescription Drug Importation Act of 2024
Latest Action
Referred to the House Committee on Energy and Commerce.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Affordable and Safe Prescription Drug Importation Act of 2024 is a House bill introduced in the 118th Congress aimed at addressing the cost and safety of prescription drugs by allowing their importation. The bill was referred to the House Committee on Energy and Commerce on June 26, 2024. However, the bill has no publicly available summary or full text, and its status is listed as Failed / Expired. The policy area is health, indicating a focus on pharmaceutical regulation and access to medications.
This bill sought to enable the importation of prescription drugs to improve affordability and safety but did not advance beyond committee referral and ultimately expired without passage.
- The bill is titled the Affordable and Safe Prescription Drug Importation Act of 2024 and was introduced in the House of Representatives.
- It was referred to the House Committee on Energy and Commerce on June 26, 2024, but no further legislative action is recorded.
- The bill's status is marked as Failed / Expired, indicating it did not become law during the 118th Congress.
['Consumers seeking more affordable prescription medications', 'Healthcare providers and pharmacies potentially accessing imported drugs', 'Regulatory agencies involved in drug safety oversight']
['Lack of publicly available full text limits understanding of specific provisions and regulatory mechanisms', 'Implementation challenges related to ensuring drug safety and compliance with importation standards', 'Oversight and enforcement authority details are not provided, raising questions about regulatory capacity', 'Potential cost implications for government agencies or private sector entities involved in importation']
The bill was introduced during the 118th Congress and referred to the House Committee on Energy and Commerce, a committee with jurisdiction over health-related legislation. The absence of further action and its Failed / Expired status suggest it did not gain sufficient legislative support or priority to advance. The bill fits within ongoing congressional efforts to address prescription drug affordability and safety but lacks detailed legislative history or debate records.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential increased access to lower-cost prescription drugs if importation mechanisms were implemented effectively', 'Possible shifts in pharmaceutical supply chains and market dynamics due to importation provisions', 'Increased regulatory workload for agencies tasked with ensuring drug safety and compliance']
The absence of a bill summary and full text limits transparency and public understanding of the bill's specific provisions and regulatory framework. The bill's referral to a key committee without further action and its expired status highlight the importance of tracking legislative progress and ensuring access to complete legislative documents for effective oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.